Non-classical transcriptional regulation of HLA-G: An update

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 2973-2989

  Moreau, Philippe ^a   Flajollet, Sébastien ^a   Carosella, Edgardo D ^a  

^a DIF   (France)

Author keywords

Epigenetics; Gene regulation; HLA G; Transcription factors

Indexed keywords

CYCLIC AMP; HEAT SHOCK PROTEIN; HLA G ANTIGEN; LEUKEMIA INHIBITORY FACTOR; PROGESTERONE; RAS PROTEIN;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ANIMAL; DNA RESPONSIVE ELEMENT; FEMALE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PREGNANCY; PROMOTER REGION; REVIEW;

3' UNTRANSLATED REGIONS; ALTERNATIVE SPLICING; ANIMALS; CYCLIC AMP; FEMALE; GENE EXPRESSION REGULATION; HEAT-SHOCK PROTEINS; HLA-G ANTIGENS; HUMANS; LEUKEMIA INHIBITORY FACTOR; PREGNANCY; PROGESTERONE; PROMOTER REGIONS, GENETIC; RAS PROTEINS; RESPONSE ELEMENTS;

EID: 77449101343     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00800.x     Document Type: Review

References (165)

1. Carosella ED, Moreau P, Lemaoult J. HLA-G: from biology to clinical benefits. Trends Immunol. 2008, 29:125-32.
2. Ellis SA, Sargent IL, Redman CWG. Evidence for a novel HLA antigen found on human extravillous trophoblast and a choriocarcinoma cell line. Immunology. 1986, 59:595-601.
3. Kovats S, Main EK, Librach C. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990, 248:220-3.
4. McMaster MT, Librach CL, Zhou Y. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol. 1995, 154:3771-8.
5. Rouas-Freiss N, Goncalves RM, Menier C. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA. 1997, 94:11520-5.
6. Fuzzi B, Rizzo R, Criscuoli L. HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur J Immunol. 2002, 32:311-5.
7. Lila N, Amrein C, Guillemain R. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation. 2002, 105:1949-54.
8. Creput C, Durrbach A, Menier C. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol. 2003, 39:587-94.
9. Qiu J, Terasaki PI, Miller J. Soluble HLA-G expression and renal graft acceptance. Am J Transplant. 2006, 6:2152-6.
10. Rouas-Freiss N, Moreau P, Menier C. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol. 2007, 17:413-21.
11. Onno M, Pangault C, Le Friec G. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol. 2000, 164:6426-34.
12. Lafon M, Prehaud C, Megret F, Lafage M, Mouillot G, Roa M, Moreau P, Rouas-Freiss N, Carosella ED. Modulation of HLA-G expression in human neural cells after neurotropic viral infections. J Virol. 2005, 79:15226-37.
13. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood. 2008, 111:4862-70.
14. Colonna M, Navarro F, Bellon T. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997, 186:1809-18.
15. Colonna M, Samaridis J, Cella M. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol. 1998, 160:3096-100.
16. Rajagopalan S, Long EO. A human histocompatibility leucocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 1999, 189:1093-9.
17. LeMaoult J, Caumartin J, Daouya M. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007, 109:2040-8.
18. Caumartin J, Favier B, Daouya M. Trogocytosis-based generation of suppressive NK cells. EMBO J. 2007, 26:1423-33.
19. Lemaoult J, Zafaranloo K, Le Danff C. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J. 2005
20. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with shortened cytoplasmic segment. Proc Natl Acad Sci USA. 1987, 84:9145-9.
21. Hviid TV. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum Reprod Update. 2006, 12:209-32.
22. Tan Z, Shon AM, Ober C. Evidence of balancing selection at the HLA-G promoter region. Hum Mol Genet. 2005, 14:3619-28.
23. Hviid TV, Rizzo R, Melchiorri L. Polymorphism in the 5′ upstream regulatory and 3′ untranslated regions of the HLA-G gene in relation to soluble HLA-G and IL-10 expression. Hum Immunol. 2006, 67:53-62.
24. Tan Z, Randall G, Fan J. Allele-Specific Targeting of microRNAs to HLA-G and Risk of Asthma. Am J Hum Genet. 2007, 81:829-34.
25. Lajoie J, Jeanneau A, Faucher MC. Characterisation of five novel HLA-G alleles with coding DNA base changes. Tissue Antigens. 2008, 72:502-4.
26. Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA. 1992, 89:3947-51.
27. Kirszenbaum M, Moreau P, Gluckman E. An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci USA. 1994, 91:4209-13.
28. Paul P, Cabestre FA, Ibrahim EC. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum. Immunol. 2000, 61:1138-49.
29. Clements CS, Kjer-Nielsen L, Kostenko L. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci USA. 2005, 102:3360-5.
30. Park B, Lee S, Kim E. The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity. 2001, 15:213-24.
31. Moreau P, Carosella E, Teyssier M. Soluble HLA-G molecule. An alternatively spliced HLA-G mRNA form candidate to encode it in peripheral blood mononuclear cells and human trophoblasts. Human Immunology. 1995, 43:231-6.
32. Fujii T, Ishitani A, Geraghty DE. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol. 1994, 153:5516-24.
33. Park GM, Lee S, Park B. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun. 2004, 313:606-11.
34. Zidi I, Guillard C, Marcou C. Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci. 2006
35. Gonen-Gross T, Achdout H, Arnon TI. The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta2-microglobulin-free HLA-G molecules. J Immunol. 2005, 175:4866-74.
36. Apps R, Gardner L, Sharkey AM. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol. 2007, 37:1924-37.
37. Morales PJ, Pace JL, Platt JS. Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells. Immunology. 2007, 122:179-88.
38. Shiroishi M, Tsumoto K, Amano K. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA. 2003, 100:8856-61.
39. Jurisicova A, Casper RF, MacLusky NJ. HLA-G expression during preimplantation human embryo development. Proc Natl Acad Sci USA. 1996, 93:161-5.
40. Menicucci A, Noci I, Fuzzi B. Non-classic sHLA class I in human oocyte culture medium. Hum. Immunol. 1999, 60:1054-7.
41. Houlihan JM, Biro PA, Harper HM. The human amnion is a site of MHC class Ib expression: evidence for the expression of HLA-E and HLA-G. J Immunol. 1995, 154:5665-74.
42. Hammer A, Hutter H, Blaschitz A. Amnion epithelial cells, in contrast to trophoblast cells, express all classical HLA class I molecules together with HLA-G. Am J Reprod Immunol. 1997, 37:161-71.
43. Blaschitz A, Lenfant F, Mallet V. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol. 1997, 27:3380-8.
44. Crisa L, Mc Master MT, Ishii JK. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med. 1997, 186:289-98.
45. Mallet V, Blaschitz A, Crisa L. HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Int Immunol. 1999, 11:889-98.
46. Le Discorde M, Moreau P, Sabatier P. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol. 2003, 64:1039-44.
47. Cirulli V, Zalatan J, McMaster M. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes. 2006, 55:1214-22.
48. Ito T, Ito N, Saathoff M. Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol. 2005, 125:1139-48.
49. Blanco O, Tirado I, Munoz-Fernandez R. Human decidual stromal cells express HLA-G: effects of cytokines and decidualization. Hum Reprod. 2008, 23:144-52.
50. Yang Y, Chu W, Geraghty DE. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J Immunol. 1996, 156:4224-31.
51. Ulbrecht M, Rehberger B, Strobel I. HLA-G: expression in human keratinocytes in vitro and in human skin in vivo. Eur J Immunol. 1994, 24:176-80.
52. Le Rond S, Le Maoult J, Creput C. Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur J Immunol. 2004, 34:649-60.
53. Fanchin R, Gallot V, Rouas-Freiss N. Implication of HLA-G in human embryo implantation. Hum Immunol. 2007, 68:259-63.
54. Urosevic M, Kurrer MO, Kamarashev J. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001, 159:817-24.
55. Pangault C, Le Friec G, Caulet-Maugendre S. Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Hum Immunol. 2002, 63:83-90.
56. Lefebvre S, Antoine M, Uzan S. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol. 2002, 196:266-74.
57. Singer G, Rebmann V, Chen YC. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003, 9:4460-4.
58. Hansel DE, Rahman A, Wilentz RE. HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer. 2005, 35:15-24.
59. Yie SM, Yang H, Ye SR. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 2007, 128:1002-9.
60. Rouas-Freiss N, Bruel S, Menier C. Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int J Cancer. 2005, 117:114-22.
61. Bukur J, Malenica B, Huber C. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol. 2003, 64:1081-92.
62. Copeman J, Han RN, Caniggia I. Posttranscriptional regulation of human leukocyte antigen G during human extravillous cytotrophoblast differentiation. Biol Reprod. 2000, 62:1543-50.
63. Onno M, Guillaudeux T, Amiot L. The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. Hum Immunol. 1994, 41:79-86.
64. Teyssier M, Bensussan A, Kirszenbaum M. Natural killer cells are the unique lymphocyte cell subset which do not express HLA-G. Nat Immun. 1995, 14:262-70.
65. Moreau P, Lefebvre S, Gourand L. Specific binding of nuclear factors to the HLA-G gene promoter correlates with a lack of HLA-G transcripts in first trimester human fetal liver. Hum Immunol. 1998, 59:751-7.
66. Paul P, Cabestre FA, Le Gal FA. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 1999, 59:1954-60.
67. Solier C, Mallet V, Lenfant F. HLA-G unique promoter region: functional implications. Immunogenetics. 2001, 53:617-25.
68. Gobin SJ, van den Elsen PJ. The regulation of HLA class I expression: is HLA-G the odd one out?. Semin Cancer Biol. 1999, 9:55-9.
69. Gobin SJ, van den Elsen PJ. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol. 2000, 61:1102-7.
70. Schmidt CM, Ehlenfeldt RG, Athanasiou MC. Extraembryonic expression of the human MHC class I gene HLA-G in transgenic mice. Evidence for a positive regulatory region located 1 kilobase 5′ to the start site of transcription. J Immunol. 1993, 151:2633-45.
71. van den Elsen PJ, Gobin SJ, van Eggermond MC. Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics. 1998, 48:208-21.
72. Gobin SJ, Keijsers V, van Zutphen M. The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J Immunol. 1998, 161:2276-83.
73. Gobin SJ, van Zutphen M, Woltman AM. Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J Immunol. 1999, 163:1428-34.
74. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol. 2001, 19:331-73.
75. Steimle V, Durand B, Barras E. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 1995, 9:1021-32.
76. Durand B, Sperisen P, Emery P. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 1997, 16:1045-55.
77. Masternak K, Barras E, Zufferey M. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet. 1998, 20:273-7.
78. Nagarajan UM, Louis-Plence P, DeSandro A. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity. 1999, 10:153-62.
79. Moreno CS, Beresford GW, Louis-Plence P. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity. 1999, 10:143-51.
80. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene. 1999, 239:15-27.
81. Gobin SJ, Peijnenburg A, Keijsers V. Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity. 1997, 6:601-11.
82. Gobin SJ, Peijnenburg A, van Eggermond M. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes. Immunity. 1998, 9:531-41.
83. van den Elsen PJ, Peijnenburg A, van Eggermond MC. Shared regulatory elements in the promoters of MHC class I and class II genes. Immunol Today. 1998, 19:308-12.
84. Martin BK, Chin KC, Olsen JC. Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity. 1997, 6:591-600.
85. Lefebvre S, Moreau P, Dausset J. Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA. Placenta. 1999, 20:293-301.
86. Gobin SJ, van Zutphen M, Westerheide SD. The MHC-specific enhanceosome and its role in MHC class I and beta(2)-microglobulin gene transactivation. J Immunol. 2001, 167:5175-84.
87. Rousseau P, Paul P, O'Brien M. The X1 box of HLA-G promoter is a target site for RFX and Sp1 factors. Hum Immunol. 2000, 61:1132-7.
88. Rousseau P, Masternak K, Krawczyk M. In vivo, RFX5 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class I protein expression in a cell type-dependent manner. Immunology. 2004, 111:53-65.
89. Sim BC, Hui KM. A HLA class I cis-regulatory element whose activity can be modulated by hormones. Int J Cancer. 1994, 59:646-56.
90. Williams KL, Taxman DJ, Linhoff MW. Cutting edge: monarch-1: a pyrin/nucleotide-binding domain/leucine-rich repeat protein that controls classical and nonclassical MHC class I genes. J Immunol. 2003, 170:5354-8.
91. Gobin SJ, Keijsers V, Cheong C. Transcriptional regulation of HLA-G. Transplant Proc. 1999, 31:1857-9.
92. Yelavarthi KK, Schmidt CM, Ehlenfeldt RG. Cellular distribution of HLA-G mRNA in transgenic mouse placentas. Journal of Immunology. 1993, 151:3638-45.
93. Strauss EC, Orkin SH. In vivo protein-DNA interactions at hypersensitive site 3 of the human beta-globin locus control region. Proc Natl Acad Sci USA. 1992, 89:5809-13.
94. Schmidt CM, Orr HT. HLA-G transgenic mice: a model for studying expression and function at the maternal/fetal interface. Immunol. Rev. 1995, 147:53-65.
95. Moreau P, Paul P, Gourand L. HLA-G gene transcriptional regulation in trophoblasts and blood cells: differential binding of nuclear factors to a regulatory element located 1.1 kb from exon 1. Hum Immunol. 1997, 52:41-6.
96. Gobin SJ, Biesta P, de Steenwinkel JE. HLA-G transactivation by cAMP-response element-binding protein (CREB). An alternative transactivation pathway to the conserved major histocompatibility complex (MHC) class I regulatory routes. J Biol Chem. 2002, 277:39525-31.
97. Yang Y, Geraghty DE, Hunt JS. Cytokine regulation of HLA-G expression in human trophoblast cell lines. J. Reprod. Immunol. 1995, 29:179-95.
98. Chu W, Gao J, Murphy WJ. A candidate interferon-gamma activated site (GAS element) in the HLA-G promoter does not bind nuclear proteins. Hum Immunol. 1999, 60:1113-8.
99. Wiendl H, Mitsdoerffer M, Hofmeister V. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002, 168:4772-80.
100. Lefebvre S, Berrih-Aknin S, Adrian F. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem. 2001, 276:6133-9.
101. Chu W, Yang Y, Geraghty DE. Interferons enhance HLA-G mRNA and protein in transfected mouse fibroblasts. J Reprod Immunol. 1999, 42:1-15.
102. Morimoto RI, Santoro MG. Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Nat Biotechnol. 1998, 16:833-8.
103. Ibrahim EC, Morange M, Dausset J. Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones. 2000, 5:207-18.
104. Yie SM, Li LH, Li GM. Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro. Hum Reprod. 2006, 21:46-51.
105. Yie SM, Xiao R, Librach CL. Progesterone regulates HLA-G gene expression through a novel progesterone response element. Hum Reprod. 2006, 21:2538-44.
106. Stewart CL, Kaspar P, Brunet LJ. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 1992, 359:76-9.
107. Nachtigall MJ, Kliman HJ, Feinberg RF. The effect of leukemia inhibitory factor (LIF) on trophoblast differentiation: a potential role in human implantation. J Clin Endocrinol Metab. 1996, 81:801-6.
108. Bamberger AM, Jenatschke S, Schulte HM. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab. 2000, 85:3932-6.
109. Shido F, Ito T, Nomura S. Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells. Endocrinology. 2006, 147:1780-8.
110. Thiagalingam A, De Bustros A, Borges M. RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas. Mol Cell Biol. 1996, 16:5335-45.
111. Shi Y, Sawada J, Sui G. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature. 2003, 422:735-8.
112. Rebmann V, van der Ven K, Passler M. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens. 2001, 57:15-21.
113. Hviid TV, Hylenius S, Rorbye C. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics. 2003, 55:63-79.
114. O'Brien M, McCarthy T, Jenkins D. Altered HLA-G transcription in pre-eclampsia is associated with allele specific inheritance: possible role of the HLA-G gene in susceptibility to the disease. Cell Mol Life Sci. 2001, 58:1943-9.
115. Hiby S, King A, Sharkey A. Molecular studies of trophoblast HLA-G: polymorphism, isoforms, imprinting and expression in preimplantation embryo. Tissue Antigens. 1999, 53:1-13.
116. Rousseau P, Le Discorde M, Mouillot G. The 14 bp deletion-insertion polymorphism in the 3′ UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol. 2003, 64:1005-10.
117. Hviid TV, Rizzo R, Christiansen OB. HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics. 2004, 56:135-41.
118. Auboeuf D, Honig A, Berget SM. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science. 2002, 298:416-9.
119. Ferretti C, Bruni L, Dangles-Marie V. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. 2007, 13:121-41.
120. Orsi NM, Gopichandran N, Ekbote UV. Murine serum cytokines throughout the estrous cycle, pregnancy and post partum period. Anim Reprod Sci. 2006, 96:54-65.
121. Orsi NM, Tribe RM. Cytokine networks and the regulation of uterine function in pregnancy and parturition. J Neuroendocrinol. 2008, 20:462-9.
122. Staun-Ram E, Shalev E. Human trophoblast function during the implantation process. Reprod Biol Endocrinol. 2005, 3:56-68.
123. Moreau P, Adrian-Cabestre F, Menier C. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol. 1999, 11:803-11.
124. Moreau P, Faure O, Lefebvre S. Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. Transplant Proc. 2001, 33:2277-80.
125. Cadet P, Rady PL, Tyring SK. Interleukin-10 messenger ribonucleic acid in human placenta: implications of a role for interleukin-10 in fetal allograft protection. Am J Obstet Gynecol. 1995, 173:25-9.
126. Dunker K, Schlaf G, Bukur J. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens. 2008, 72:137-48.
127. Sebti Y, Le Friec G, Pangault C. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol. 2003, 64:1093-101.
128. Makris A, Xu B, Yu B. Placental deficiency of interleukin-10 (IL-10) in preeclampsia and its relationship to an IL10 promoter polymorphism. Placenta. 2006, 27:445-51.
129. Goldman-Wohl DS, Ariel I, Greenfield C. HLA-G expression in extravillous trophoblasts is an intrinsic property of cell differentiation: a lesson learned from ectopic pregnancies. Mol Hum Reprod. 2000, 6:535-40.
130. Urosevic M, Dummer R. HLA-g and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol. 2003, 13:337-42.
131. Spencer JV, Lockridge KM, Barry PA. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol. 2002, 76:1285-92.
132. Gros F, Sebti Y, de Guibert S. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia. 2006, 8:223-30.
133. Amiot L, Onno M, Drenou B. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum Immunol. 1998, 59:524-8.
134. Onno M, Le Friec G, Pangault C. Modulation of HLA-G antigens expression in myelomonocytic cells. Hum Immunol. 2000, 61:1086-94.
135. Genbacev O, Zhou Y, Ludlow JW. Regulation of human placental development by oxygen tension. Science. 1997, 277:1669-72.
136. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006, 441:437-43.
137. Mazure NM, Brahimi-Horn MC, Berta MA. HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem Pharmacol. 2004, 68:971-80.
138. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med. 2007, 85:1301-7.
139. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999, 15:551-78.
140. Gray MJ, Zhang J, Ellis LM. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005, 24:3110-20.
141. Chang CC, Ferrone S. HLA-G in melanoma: can the current controversies be solved?. Semin Cancer Biol. 2003, 13:361-9.
142. Mouillot G, Marcou C, Zidi I. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol. 2007, 68:277-85.
143. Nagamatsu T, Fujii T, Yamashita T. Hypoxia does not reduce HLA-G expression on extravillous cytotrophoblasts. J Reprod Immunol. 2004, 63:85-95.
144. Polakova K, Bandzuchova E, Tirpakova J. Modulation of HLA-G expression. Neoplasma. 2007, 54:455-62.
145. Kilburn BA, Wang J, Duniec-Dmuchowski ZM. Extracellular matrix composition and hypoxia regulate the expression of HLA-G and integrins in a human trophoblast cell line. Biol Reprod. 2000, 62:739-47.
146. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007, 447:407-12.
147. Nafee TM, Farrell WE, Carroll WD. Epigenetic control of fetal gene expression. BJOG. 2008, 115:158-68.
148. Chelbi ST, Vaiman D. Genetic and epigenetic factors contribute to the onset of preeclampsia. Mol Cell Endocrinol. 2008, 282:120-9.
149. Esteller M. Epigenetics in cancer. N Engl J Med. 2008, 358:1148-59.
150. Boucraut J, Guillaudeux T, Alizadeh M. HLA-E is the only class I gene that escapes CpG methylation and is transcriptionally active in the trophoblast-derived human cell line JAR. Immunogenetics. 1993, 38:117-30.
151. Guillaudeux T, Rodriguez AM, Girr M. Methylation status and transcriptional expression of the MHC class I loci in human trophoblast cells from term placenta. J Immunol. 1995, 154:3283-99.
152. Moreau P, Mouillot G, Rousseau P. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA. 2003, 100:1191-6.
153. Mouillot G, Marcou C, Rousseau P. HLA-G gene activation in tumor cells involves cis-acting epigenetic changes. Int J Cancer. 2005, 113:928-36.
154. Yan WH, Lin AF, Chang CC. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2′-deoxycytidine. Cell Res. 2005, 15:523-31.
155. Seliger B, Schlaf G. Structure, expression and function of HLA-G in renal cell carcinoma. Semin Cancer Biol. 2007, 17:444-50.
156. Polakova K, Bandzuchova E, Kuba D. Demethylating agent 5-aza-2′-deoxycytidine activates HLA-G expression in human leukemia cell lines. Leuk Res. 2009, 33:518-24.
157. Onno M, Amiot L, Bertho N. CpG methylation patterns in the 5′ part of the nonclassical HLA-G gene in peripheral blood CD34+ cells and CD2+ lymphocytes. Tissue Antigens. 1997, 49:356-64.
158. Menendez L, Walker LD, Matyunina LV. Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors. Mol Cancer. 2008, 7:43-54.
159. Chang CC, Murphy SP, Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol. 2003, 64:1057-63.
160. Chan HW, Kurago ZB, Stewart CA. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med. 2003, 197:245-55.
161. Li G, Weyand CM, Goronzy JJ. Epigenetic mechanisms of age-dependent KIR2DL4 expression in T cells. J Leukoc Biol. 2008, 824:824-34.
162. Rebmann V, Regel J, Stolke D. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003, 13:371-7.
163. Ugurel S, Rebmann V, Ferrone S. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001, 92:369-76.
164. Bukur J, Rebmann V, Grosse-Wilde H. Functional role of human leukocyte antigen-g up-regulation in renal cell carcinoma. Cancer Res. 2003, 63:4107-11.
165. Nagamatsu T, Fujii T, Ishikawa T. A primary cell culture system for human cytotrophoblasts of proximal cytotrophoblast cell columns enabling in vitro acquisition of the extra-villous phenotype. Placenta. 2004, 25:153-65.